Advertisement
Canada markets open in 7 hours 7 minutes
  • S&P/TSX

    21,871.96
    +64.59 (+0.30%)
     
  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     
  • DOW

    38,239.98
    +253.58 (+0.67%)
     
  • CAD/USD

    0.7297
    -0.0004 (-0.05%)
     
  • CRUDE OIL

    83.02
    +0.17 (+0.21%)
     
  • Bitcoin CAD

    91,276.79
    +415.50 (+0.46%)
     
  • CMC Crypto 200

    1,403.53
    -11.23 (-0.79%)
     
  • GOLD FUTURES

    2,319.80
    -26.60 (-1.13%)
     
  • RUSSELL 2000

    1,967.47
    +19.82 (+1.02%)
     
  • 10-Yr Bond

    4.6230
    +0.0080 (+0.17%)
     
  • NASDAQ futures

    17,330.75
    -19.25 (-0.11%)
     
  • VOLATILITY

    16.94
    -1.77 (-9.46%)
     
  • FTSE

    8,023.87
    +128.02 (+1.62%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • CAD/EUR

    0.6855
    +0.0005 (+0.07%)
     

Will Jazz Pharma's Stock Awake With Q2 Earnings?

With Q2 earnings due Aug. 5, Jazz Pharmaceuticals is testing a new buy point. The maker of narcolepsy-related treatment Xyrem is in the No. 7-ranked Medical - Ethical Drugs industry group, which also includes top-rated drugmakers Horizon Pharmaceuticals and Valeant Pharmaceuticals.